Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New glasses could help kids see better longer

NCT ID NCT05174780

Disease control Sponsor: Essilor International Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new type of spectacle lens designed to slow the progression of myopia (nearsightedness) in children. 159 kids aged 6 to 12 wore either the test lens or a standard lens. Researchers measured changes in eye length and prescription strength over time to see if the innovative lens was safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
innovative myopia control spectacle lens
What this could lead to
If proven effective, this lens could offer a simple, non-invasive way to slow worsening nearsightedness in children, reducing the need for stronger prescriptions.
What could go wrong
The trial is completed but results are not yet widely published. The effect may be modest, and not all children may benefit equally. Long-term safety and effectiveness beyond the study period are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

159 people

The number who actually took part.

Started

Dec 2021

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 12 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Equal to or greater than 6 years and not older than 12 years at time of informed consent and assent. * Spherical equivalent refractive error (SER) by manifest refraction between -0.75 and -4.50 D in each eye. * Astigmatism, if present, of not more than 1.50 D. * Difference in SER between the two eyes (Anisometropia) by manifest refraction not more than 1.00 D. * Best corrected visual acuity in each eye equal to or better than +0.10 logMAR (≥ 20/25 as Snellen) * Agree to wear spectacles for ≥10 hours/day at least 6 days/week. * Willingness and ability to participate in trial for 3 years and attend scheduled visits. Exclusion Criteria: * History of myopia control intervention (e.g., atropine, orthokeratology, multifocal contact lenses, etc.) * Strabismus by cover test at near or distance wearing correction. * Amblyopia * Any ocular or systemic condition known to affect refractive status (e.g., keratoconus, diabetes, Down's syndrome, etc.). * Current use of ocular or systemic medications which, in the investigator's opinion, may significantly affect pupil size, accommodation or refractive state. * Current or anticipated use of growth hormones. * Participation in any clinical study within 30 days of the Baseline visit.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myopia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myopia

Contacts and locations

Locations

  • Illinois College of Optometry

    Chicago, Illinois, 60616, United States

  • Kannarr Eye Care

    Pittsburg, Kansas, 66762, United States

  • Mann Eye Institute

    Houston, Texas, 77002, United States

  • New England College of Optometry

    Boston, Massachusetts, 02115, United States

  • SUNY College of Optometry

    New York, New York, 10036, United States

  • Sabal Eye Care

    Longwood, Florida, 32779, United States

  • Sacco Eye Group

    Vestal, New York, 13850, United States

  • Scripps Poway Optometry

    San Diego, California, 92131, United States

  • UPMC Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania, 15224, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.